TT125-802, a highly selective, well-tolerated bromodomain inhibitor of CBP/p300 with anti-tumor activity in patients with advanced solid tumors: An update on the ongoing phase I study. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results